Evidence map›Paper›PMID 26288839›Full record

ArticleEBioMedicine2015

The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis.

Mitchell S Stark, Kerenaftali Klein, Benjamin Weide, Lauren E Haydu, Annette Pflugfelder, Yue Hang Tang, Jane M Palmer, David C Whiteman, Richard A Scolyer, Graham J Mann and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Predictive Performance of Serum S100BFrontiers in oncology · 2021
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Review
  9. Review
  10. The multifaceted roles of ribosomal P complex in cancer.World journal of surgical oncology · 2025
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Liquid biopsy for diagnostic and prognostic evaluation of melanoma.Frontiers in cell and developmental biology · 2024
    Review
  18. Review
  19. Review
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Mitchell S StarkOncogenomics Group, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, Australia ; School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD 4059, Australia.
Kerenaftali KleinStatistics Unit, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, Australia ; Clinical Trials and Biostatistics Unit, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, Australia.
Benjamin WeideDepartment of Dermatology, University Medical Center, Tubingen, Germany.
Lauren E HayduMelanoma Institute Australia, Sydney, NSW, Australia ; The University of Sydney, Sydney Medical School, Sydney, Australia.
Annette PflugfelderDepartment of Dermatology, University Medical Center, Tubingen, Germany ; Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia.
Yue Hang TangSurgical Oncology Group, The University of Queensland, School of Medicine, Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland, Australia.
Jane M PalmerOncogenomics Group, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, Australia.
David C WhitemanCancer Control Group, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, Australia.
Richard A ScolyerMelanoma Institute Australia, Sydney, NSW, Australia ; The University of Sydney, Sydney Medical School, Sydney, Australia.
Graham J MannMelanoma Institute Australia, Sydney, NSW, Australia ; The University of Sydney, Sydney Medical School, Sydney, Australia.
John F ThompsonMelanoma Institute Australia, Sydney, NSW, Australia ; The University of Sydney, Sydney Medical School, Sydney, Australia.
Georgina V LongMelanoma Institute Australia, Sydney, NSW, Australia ; The University of Sydney, Sydney Medical School, Sydney, Australia.
Andrew P BarbourSurgical Oncology Group, The University of Queensland, School of Medicine, Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland, Australia.
H Peter SoyerDermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia.
Claus GarbeDepartment of Dermatology, University Medical Center, Tubingen, Germany.
Adrian HeringtonSchool of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD 4059, Australia.
Pamela M PollockSchool of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD 4059, Australia.
Nicholas K HaywardOncogenomics Group, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The overall 5-year survival for melanoma is 91%. However, if distant metastasis occurs (stage IV), cure rates are < 15%. Hence, melanoma detection in earlier stages (stages I-III) maximises the chances of patient survival. We measured the expression of a panel of 17 microRNAs (miRNAs) (MELmiR-17) in melanoma tissues (stage III; n = 76 and IV; n = 10) and serum samples (collected from controls with no melanoma, n = 130; and patients with melanoma (stages I/II, n = 86; III, n = 50; and IV, n = 119)) obtained from biobanks in Australia and Germany. In melanoma tissues, members of the 'MELmiR-17' panel were found to be predictors of stage, recurrence, and survival. Additionally, in a minimally-invasive blood test, a seven-miRNA panel (MELmiR-7) detected the presence of melanoma (relative to controls) with high sensitivity (93%) and specificity (≥ 82%) when ≥ 4 miRNAs were expressed. Moreover, the 'MELmiR-7' panel characterised overall survival of melanoma patients better than both serum LDH and S100B (delta log likelihood = 11, p < 0.001). This panel was found to be superior to currently used serological markers for melanoma progression, recurrence, and survival; and would be ideally suited to monitor tumour progression in patients diagnosed with early metastatic disease (stages IIIa-c/IV M1a-b) to detect relapse following surgical or adjuvant treatment.

Indexed as

Gene Expression Regulation, NeoplasticAdultCohort StudiesDisease ProgressionFemaleGene Expression ProfilingHumansMaleMelanomaMicroRNAsMiddle AgedMultivariate AnalysisNeoplasm StagingPredictive Value of TestsPrognosisSensitivity and SpecificityMicroRNAsAGO2, argonaute RISC catalytic component 2AJCC, American Joint Committee on CancerAUC, area under the curveAUROC, area under the receiver operator curveBiomarkerCI, confidence intervalCt, threshold cycleDiagnosticDOR, diagnostic odds ratioFFPE, formalin-fixed paraffin-embeddedHR, hazard ratioLDH, lactate dehydrogenaseM1a, metastasis to skin, subcutaneous (below the skin) tissue, or lymph nodes in distant parts of the body, with a normal blood LDH levelM1b, metastasis to the lungs, with a normal blood LDH levelM1c, metastasis to any other organs, OR distant spread to any site along with an elevated blood LDH levelMelanomaMIA, Melanoma Institute of AustraliaMicroRNAmiR, microRNAMiRNAmiRNA, microRNANA, not applicableNM, nodular melanomaN stage, nodal or number of lymph nodes stageOR, odds ratioPD1, programmed cell death proteinPrognosticRNA, ribonucleic acidS100B, S100 calcium-binding protein BSMM, superficial spreading melanomaUSA, United States of America

Identifiers

PMID26288839
PMCPMC4534690

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.